RxDoctor Payments Data

Nhi Huynh, MD

Psychiatry · San Jose, CANPI 1710066642

Payments from drug & device makers

$7,018in general payments, 2019–2025

Across 110 payments — averaging $63.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$1K
  • AbbVie$914
  • Teva Pharmaceuticals USA, Inc.$864
  • Otsuka America Pharmaceutical, Inc.$495
  • AstraZeneca$478
  • GSK$466
  • plus $3K from 16 others

What the payments were for

  • Food & beverage$6,88398%
  • Education$1352%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,018 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$28,848
Medicare patients
45
Services billed
311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate27$71,021
Abilify MaintenaAripiprazole25$55,665
Lurasidone Hcl22$13,552
Aripiprazole56$3,017
Quetiapine Fumarate73$2,034
Olanzapine80$1,627
Sertraline Hcl250$1,394
Bupropion Hcl SrBupropion Hcl30$820
Mirtazapine33$406
Buspirone Hcl76$398
Benztropine Mesylate22$393
Hydroxyzine Pamoate30$337
Trazodone Hcl41$321
Gabapentin26$239
Fluoxetine Hcl37$197

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$390$71,02127 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$495$55,66525 claims
Lilly USA, LLCOlanzapine$173$1,62780 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.

Other psychiatry in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →